🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million infections per year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the highly restricted available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to data published in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The research included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in many developing nations.

Medical professionals directly involved have expressed optimism. Having a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the disease for patients and to stop the proliferation of untreatable gonorrhoea worldwide.